Overall, 34 patients (19.3%) of patients with R/R AML achieved CR with enasidenib, with a slight advantage in IDH2-R172 mutations (24.4%) vs. IDH2-R140 (17.7%). This evidence concerns the gene IDH2 and acute myeloid leukemia.